Ellen Schlichting

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Per Eystein Lønning, Jürgen Geisler, Lars Erik Krag et al. · Journal of Clinical Oncology · 2005 · 294 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer

Gro Wiedswang, Elin Borgen, Rolf Kåresen et al. · Journal of Clinical Oncology · 2003 · 287 citations

Medicine, Cell Biology, Oncology +16

Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients

Hege G. Russnes, Hans Kristian Moen Vollan, Ole Christian Lingjærde et al. · Science Translational Medicine · 2010 · 153 citations

Medicine, Genetics, Oncology +17

Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008

Olaf Johan Hartmann-Johnsen, Rolf Kåresen, Ellen Schlichting et al. · Annals of Surgical Oncology · 2015 · 152 citations · Full text

Medicine, Oncology, Surgery +14

DNA methylation patterns in luminal breast cancers differ from non‐luminal subtypes and can identify relapse risk independent of other clinical variables

Sitharthan Kamalakaran, Vinay Varadan, Hege Russnes et al. · Molecular Oncology · 2010 · 148 citations · Full text

Life Sciences, Molecular Biology, Oncology +17